59 results about "Bismuth / pectin" patented technology

The invention relates to a colloid bismuth pectin compound and a quality control method of pharmaceutical compositions of the colloid bismuth pectin compound, and specifically provides a colloid bismuth pectin compound, new quality control indexes of pharmaceutical compositions of the colloid bismuth pectin compound and a detection method of the colloid bismuth pectin compound and the pharmaceutical compositions of the colloid bismuth. In the prior art, the quality of products having poor efficacy can not be well controlled because the efficacy-related indexes are not controlled strictly in the existing quality control methods of colloid bismuth pectin and pharmaceuticals thereof. Based on the existing quality control methods of colloid bismuth pectin and pharmaceuticals thereof, the following detection items and indexes are added: intrinsic viscosity, gel property, uniformity and galacturonic acid content. The invention can effectively ensure clinical efficacy of products, make the product quality standards more scientific, reasonable and controllable, and has great significance in quality control of the colloid bismuth pectin and the pharmaceutical preparation of colloid bismuth pectin.

The invention provides a colloidal bismuth pectin capsule. In the colloidal bismuth pectin capsule, aerosil and pregelatinized starch are mixed with colloidal bismth pectin in a specific proportion.

The invention discloses a preparation method of medical micromolecular pectin. The method comprises the following steps of pretreatment, extraction, separation, purification and drying. The cellulaseand nitric acid are used for treatment; the extraction time is about 2 hours. Compared with a conventional acidolysis method, the preparation method has the advantages that the extraction efficiency can be greatly improved; the pectin molecules can be more dispersed through cellulase; the content of small molecule pectin in the solution is further improved; vacuum concentration and alcohol precipitation are used for purifying small molecule pectin; the purification purity is higher; the impurity content is small; the quality of the small molecule pectin is very good. The process design is reasonable; the obtained small molecule pectin has very good use effects in aspects of capsules of colloidal bismuth pectin capsules and the like.

The invention relates to a comprehensive wastewater treatment method for bismuth pectin bulk drugs, acridone acetic acid, acyclovir and thiodipropionate medical intermediates. The method comprises thefollowing steps: 1) performing wastewater desalination; 2) adjusting the pH of the wastewater; 3) carrying out pH acidification treatment on the wastewater; (4) carrying out Fenton reaction; 5) performing wastewater pH back-regulation treatment; 6) performing hydrolytic acidification of the wastewater; 7) performing anaerobic treatment on the wastewater; 8) performing AO reaction; 9) performing secondary precipitation; 10) flocculating and precipitating: adding 10% by mass of PAC and 0.1% by mass of PAM into a flocculation sedimentation tank; enabling the wastewater to react for 0.5 to 1h ina flocculation sedimentation tank; allowing part of sludge generated in the reaction process to flow back to the anoxic tank, enabling residual sludge to enter a sludge tank, and discharging supernatethrough a wastewater up-to-standard discharge pipeline; according to the present invention, the method has characteristics of low cost, convenient operation management, reduced wastewater pollutant concentration, and thus further reaching treatment standard, effective removing COD, BOD and NH3-N, achieving discharge standard, and providing huge social and economic benefits.

The invention discloses a compound preparation for treating broiler proventriculitis. The compound preparation comprises 1-5wt% of a proton pump inhibitor, 5-30wt% of vitamin U, 3-15wt% of colloidal bismuth pectin and 50-91wt% of a filler. The composition of the compound preparation is screened and optimized, medicines have very good synergistic effects, and the compound preparation has the advantages of low medicine cost, simple production technology and controllable quality. The clinic effective rate of the compound preparation to proventriculitis initiated by feed replacement, moldiness and environment stress reaches above 94%, the clinic cure rate of one treatment course reaches 90%, the compound preparation has an obviously better clinic effect than the single proton pump inhibitor, the treatment course of the compound preparation is shortened to 3d from that of the proton pump inhibitor of 5-7d, the clinic effective rate increases by 6%, and the cure rate increases by 18%. The compound preparation can be used as a combined medicine for treating broiler proventriculitis initiated by virus or bacterium infection, helps broiler flocks recover stomach and intestine digestion functions, and rapidly recovers the feed intake.

The invention discloses a preparation method of a high-purity colloidal bismuth pectin compound, confirmation of a chemical structural formula, a molecular formula and the molecular weight thereof, and an application technology. The compound is different from a compound prepared by a colloidal bismuth pectin preparation method (patent) disclosed and implemented previously. According to the original patent process, due to reasons of raw materials in an intermediate liquid pectin and a bismuth salt solution for the production of colloidal bismuth pectin and the preparation method thereof, the product contains lots of organic impurities (sorbitol, pectin, etc.) and inorganic impurities (nitrate and bismuth hydroxide), purity of the product is low (only 80%), quality standard level is low, and curative effect is poor. The invention provides several preparation methods for preparation of a high-purity (98%) colloidal bismuth pectin compound, including five optimization methods. Through spectrometry and analysis, the structural formula, the molecular formula and the molecular weight of the compound are determined. A novel medicinal preparation prepared from the high-purity compound has obvious clinical advantages.

A dispersion preparation containing colloidal bismuth pectin is provided. 1 g is adopted as a unit for the preparation. Each unit of the preparation includes: 44.0 to 900.0 mg of colloidal bismuth pectin, 1.0-500 mg of a penetration enhancer, 2.0-312.5 mg of acid-source pore forming agent, 2.0-250.0 mg of alkali-source pore forming agent and 1.0-400.0 mg of a disintegrating agent.

The invention discloses a pharmaceutical composition for treating helicobacter pylori infection and application of the pharmaceutical composition. The pharmaceutical composition is prepared from, by weight, 7.5-40 parts of proton pump inhibitor, 150-1000 parts of antibiotic, 220-300 parts of bismuth agent and 60-140 parts of volatile extracts, wherein the proton pump inhibitor is selected from one of omeprazole, lansoprazole, esomeprazole, pantoprazole and rabeprazole; the antibiotic is selected from one of amoxicillin, clarithromycin, levofloxacin, metronidazole, furazolidone, tetracycline and minocycline; the bismuth agent is selected from one of bismuth potassium citrate, colloidal bismuth subcitrate and colloidal bismuth pectin; the volatile extracts are volatile components extracted from chenopodium ambrosioides and twigs and leaves of Pilular Adina. By means of the pharmaceutical composition, the eradication rate of helicobacter pylori can be improved, the effective rate is increased, and the drug resistance rate and the rate of adverse reactions are reduced.

The invention provides a colloidal bismuth pectin capsule preparation and a preparation process therefor. A capsule shell of the capsule is a hollow capsule shell containing hydroxypropyl starch. The capsule has good dispersion uniformity and uniform drug concentration in a gastric acid environment, and the preparation process is simple.

The invention discloses a compound oral liquid for treating children diarrhea and a preparation method thereof. The compound oral liquid for treating the children diarrhea comprises the following components of Nutrilite Double powder, dideoxyinosine, gastrodia elata polypeptide, disaccharidase, ribavirin, racecadotril, bismuth pectin, hydrotalcite, dry yeast, probiotics, potassium chloride, sodium chloride, sodium lactate, calcium gluconate, corrigent, emulsifying agent, buffer liquid, and antioxidant. The compound oral liquid for treating the children diarrhea has the advantages that the environment of children gastrointestinal tracts is improved, the effective microbial community is increased, the digestion and adsorbing of gastrointestinal tract are promoted, the water-electrolyte metabolic disorder is prevented, and the body immunity is improved; the cost is low, the toxic or side effect is little, the compound oral liquid can be used for a long time, and the children diarrhea can be prevented and thoroughly cured after long-time administration.

The invention provides a pharmaceutical composition for treating gastric ulcer. The pharmaceutical composition comprises colloidal bismuth pectin and omeprazole, wherein colloidal bismuth pectin and omeprazole have synergistic treatment effects.

The invention provides a method for detecting free bismuth in colloidal bismuth pectin or a preparation containing colloidal bismuth pectin. The method includes the following steps of: placing colloidal bismuth pectin or the preparation containing colloidal bismuth pectin in a plastic centrifuge tube, adding water to shake for no more than 1min, obtaining a colloidal solution with uniform dissolution, centrifuging the colloidal solution immediately, separating the supernatant, measuring the content of bismuth in the supernatant by complexometric titration or ultraviolet spectrophotometry, andcalculating the content of free bismuth in colloidal bismuth pectin or the preparation containing colloidal bismuth pectin. The method for detecting free bismuth in colloidal bismuth pectin or the preparation containing colloidal bismuth pectin, established by the invention, has the advantages of strong specificity, high accuracy, good repeatability, good linear relationship and high sensitivity,and can be used as a mass control method for free bismuth in colloidal bismuth pectin or the preparation containing colloidal bismuth pectin to effectively control the quality of products of colloidalbismuth pectin or the preparation thereof.

The invention discloses a colloidal bismuth pectin capsule containing a galangal extract and a preparation method of the colloidal bismuth pectin capsule. The colloidal bismuth pectin capsule containing the galangal extract is prepared from the following raw materials in parts by weight: 30 to 50 parts of colloidal bismuth pectin according to bismuth, 4 to 10 parts of the galangal extract, 80 to 160 parts of a filler, 7 to 11 parts of a disintegrating agent, 2 to 4 parts of talcum powder, 2 to 6 parts of an adhesive, 0.2 to 2.8 parts of a lubricating agent and 4 to 8 parts of gastric solubility opadry powder. The raw materials of the colloidal bismuth pectin capsule are reasonable in formula, and the prepared colloidal bismuth pectin capsule has a uniform and complete appearance; from protection of gastric mucosa, improvement of the immunity of a human body and improvement of the antibacterial ability of the human body, effects of quickly relieving gastric ulcer diseases and fundamentally curing gastric ulcer.

The invention provides streptococcus lactis enteric-coated tablets inhibiting helicobacter pylori (HP) and a preparation method thereof. The streptococcus lactis enteric-coated tablets are prepared from streptococcus lactis, colloidal bismuth pectin, furazolidone, spirulina, vitamin U, soybean lecithin, diethyl phthalate, polyacrylic acid resin No. 2, Tween-80, castor oil, polyethylene glycol-6000, xanthan gum, talc and starch. According to a formula, the streptococcus lactis is used as a main active ingredient for treating the helicobacter pylori; the spirulina is suitable for mucosa repair,regeneration and normal secretion of intestinal ulceration formed by helicobacter pylori pathogens; the soybean lecithin has the effects of nourishing the stomach, sterilizing and repairing gastric mucosae; the colloidal bismuth pectin has the effects of isolating gastric acid, protecting injured mucosae and killing the helicobacter pylori. The streptococcus lactis enteric-coated tablets providedby the invention achieves significant inhibiting and infiltrating effects for the treatment of the helicobacter pylori; meanwhile, the mucosal injury and ulceration of the gastrointestinal tract caused by the helicobacter pylori can be alleviated and repaired.